Clinical Trials Browser

Phase 1 × Suspended × polatuzumab vedotin × Clear all

NCT06015880 2026-03-19

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Suspended

Lymphoma, Large B-Cell, Diffuse